Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells

Vascular Cell

Volumn 6, Issue 1, 2014, Pages

  Chinchar, Edmund ^a,b   Makey, Kristina L ^a,b   Gibson, John ^a   Chen, Fang ^a,b   Cole, Shelby A ^a,b   Megason, Gail C ^a   Vijayakumar, Srinivassan ^a   Miele, Lucio ^a   Gu, Jian Wei ^a,b  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Apoptosis; Basal like triple negative breast cancer; Breast cancer stem cell; Migration; Notch 1; Proliferation; Sunitinib; Xenografts

Indexed keywords

NOTCH1 RECEPTOR; SUNITINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL PROTOCOL; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAMMARY GLAND; MCF 7 CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; WESTERN BLOTTING;

MUS;

EID: 84902247735     PISSN: None     EISSN: 2045824X     Source Type: Journal    
DOI: 10.1186/2045-824X-6-12     Document Type: Article

References (46)

1. Triple-negative breast cancer. Foulkes WD, Smith IE, Reis-Filho JS, N Engl J Med 2010 363 1938 1948 10.1056/NEJMra1001389 21067385
2. Triple-negative breast cancer. Elias AD, Am J Clin Oncol 2010 33 637 645 10.1097/COC.0b013e3181b8afcf 20023571
3. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MCU, Nielsen TO, Moorman PG, Earp HS, Millikan RC, JAMA 2006 295 2492 2502 10.1001/jama.295.21. 2492 16757721
4. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. Weigelt B, Baehner FL, Reis-Filho JS, J Pathol 2010 220 263 280 19927298
5. Mechanisms of disease: angiogenesis and the management of breast cancer. Banerjee S, Dowsett M, Ashworth A, Martin LA, Nat Clin Pract Oncol 2007 4 9 536 550 10.1038/ncponc0905 17728712
6. Deciphering the anticancer mechanisms of sunitinib. Pal SK, Figlin RA, Yu H, Cancer Biol Ther 2010 10 712 714 10.4161/cbt.10.7.13130 20716960
7. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Paulsson J, Sjöblom T, Micke P, Pontén F, Landberg G, Heldin CH, Bergh J, Brennan DJ, Jirström K, Ostman A, Am J Pathol 2009 175 334 341 10.2353/ajpath.2009. 081030 19498003
8. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Goswami S, Sahai E, Wyckoff JB, Cammer M, Cox D, Pixley FJ, Stanley ER, Segall JE, Condeelis JS, Cancer Res 2005 65 5278 5283 10.1158/0008-5472.CAN-04-1853 15958574
9. Quantitative immunohistochemical expression of c Kit in breast carcinomas is predictive of patients' outcome. Charpin C, Giusiano S, Charfi S, Secq V, Carpentier S, Andrac L, Lavaut MN, Allasia C, Bonnier P, Garcia S, Br J Cancer 2009 101 48 54 10.1038/sj.bjc.6605113 19513067
10. Frequent KIT and epidermal growth factor receptor overexpressions in undifferentiated-type breast carcinomas with 'stem-cell-like' features. Tsuda H, Tani Y, Weisenberger J, Kitada S, Hasegawa T, Murata T, Tamai S, Hirohashi S, Matsubara O, Natori T, Cancer Sci 2005 96 333 339 10.1111/j.1349-7006.2005. 00060.x 15958055
11. SU11248, a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells. Young E, Miele L, Tucker KB, Huang M, Wells J, Gu JW, Cancer Biol Ther 2010 10 703 711 10.4161/cbt.10.7.12904 20686367
12. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM, Clin Cancer Res 2004 10 5367 5374 10.1158/1078-0432.CCR-04-0220 15328174
13. Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Thike AA, Cheok PY, Jara-Lazaro AR, Tan B, Tan P, Tan PH, Mod Pathol 2010 23 123 133 10.1038/modpathol.2009.145 19855377
14. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Keast PK, Brassard JA, O'Farrell AM, Cherrington JM, Pryer NK, Clin Exp Metastasis 2003 20 757 766 14713109
15. Drug-induced vessel remodeling in bone metastases as assessed by dynamic contrast enhanced magnetic resonance imaging and vessel size imaging: a longitudinal In vivo study. Bäuerle T, Merz M, Komljenovic D, Zwick S, Semmler W, Clin Cancer Res 2010 16 3215 25 10.1158/1078-0432.CCR-09-2932 20530698
16. The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts. Bello E, Taraboletti G, Colella G, Zucchetti M, Forestieri D, Licandro SA, Berndt A, Richter P, D'Incalci M, Cavalletti E, Giavazzi R, Camboni G, Damia G, Mol Cancer Ther 2013 12 131 140 23270924
17. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, Clouthier SG, Wicha MS, Proc Natl Acad Sci U S A 2012 109 2784 2789 10.1073/pnas.1018866109 22308314
18. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD, J Clin Oncol 2008 26 1810 1816 10.1200/JCO.2007.14.5375 18347007
19. Angiogenesis: an organizing principle for drug discovery? Folkman J, Nat Rev Drug Discov 2007 6 273 286 10.1038/nrd2115 17396134
20. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Johannsen M, Flörcken A, Bex A, Roigas J, Cosentino M, Ficarra V, Kloeters C, Rief M, Rogalla P, Miller K, Grünwald V, Eur Urol 2009 55 1430 1438 10.1016/j.eururo.2008.10.021 18950936
21. Modes of resistance to anti-angiogenic therapy. Bergers G, Hanahan D, Nat Rev Cancer 2008 8 592 603 10.1038/nrc2442 18650835
22. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Lu X, Kang Y, Clin Cancer Res 2010 16 5928 5935 10.1158/1078-0432.CCR-10-1360 20962028
23. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, McKay RD, Engh J, Iwama T, Kunisada T, Kassam AB, Pollack IF, Park DM, Oncogene 2009 28 3949 3959 10.1038/onc.2009.252 19718046
24. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Seidel S, Garvalov BK, Wirta V, von Stechow L, Schänzer A, Meletis K, Wolter M, Sommerlad D, Henze AT, Nistér M, Reifenberger G, Lundeberg J, Frisén J, Acker T, Brain 2010 133 Pt 4 983 995 20375133
25. Mammary stem cells and breast cancer-role of Notch signaling. Farnie G, Clarke RB, Stem Cell Rev 2007 3 169 175 10.1007/s12015-007-0023-5 17873349
26. Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. Farnie G, Clarke RB, Spence K, Pinnock N, Brennan K, Anderson NG, Bundred NJ, J Natl Cancer Inst 2007 99 616 627 10.1093/jnci/djk133 17440163
27. Notch signals in the endothelium and cancer "stem-like" cells: opportunities for cancer therapy. Gu JW, Rizzo P, Pannuti A, Golde T, Osborne B, Miele L, Vasc Cell 2012 4 7 10.1186/2045-824X-4-7 22487493
28. Increased expression of vascular endothelial growth factor and capillary density in hearts of spontaneously hypertensive rats. Gu JW, Fortepiani L, Reckelhoff JF, Adair TH, Wang J, Hall JE, Microcirculation 2004 11 689 697 10.1080/10739680490517749 15726836
29. Ethanol stimulates tumor progression and expression of vascular endothelial growth factor in chick embryos. Gu JW, Bailey AP, Sartin A, Makey I, Brady AL, Cancer 2005 103 422 431 10.1002/cncr.20781 15597382
30. Crosstalk between PKC and Notch-4 in endocrine-resistant breast cancer cells. Yun J, Pannuti A, Espinoza I, Zhu H, Hicks C, Zhu X, Rizzo P, D'Souza G, Backus K, Denning MF, Coon J, Sun M, Bresnick EH, Osipo C, Wu J, Strack PR, Tonetti DA, Miele L, Oncogenesis 2013 2 60 10.1038/oncsis.2013.26 23917222
31. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Brown LF, Berse B, Jackman RW, Tognazzi K, Guiddi AJ, Dvorak HF, Senger DR, Connolly JL, Schnitt SJ, Hum Pathol 1995 26 86 91 10.1016/0046-8177(95)90119-1 7821921
32. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT-1. Lee TH, Seng S, Sekine M, Hinton C, Fu Y, Avraham HK, Avraham S, PLoS Med 2007 4 1101 1115
33. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, Lockwood G, Egan SE, Cancer Res 2005 65 8530 8537 10.1158/0008-5472.CAN-05-1069 16166334
34. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. Nofech-Mozes S, Trudeau M, Kahn HK, Dent R, Rawlinson E, Sun P, Narod SA, Hanna WM, Breast Cancer Res Treat 2009 118 131 137 10.1007/s10549-008-0295-8 19189211
35. Triple negative tumours: a critical review. Reis-Filho JS, Tutt AN, Histopathology 2008 52 108 118 18171422
36. A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. Guerin E, Man S, Xu P, Kerbel RS, Cancer Res 2013 73 2743 2748 10.1158/0008-5472.CAN-12-4183 23610448
37. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis. Kerbel RS, Guerin E, Francia G, Xu P, Lee CR, Ebos JM, Man S, Breast 2013 22 Suppl 2 57 S65 24074794
38. Expression of vascular endothelial growth factor, its receptor and other angiogenic factors in human breast cancer. Yoshiji H, Gomez DE, Shibuya M, Thorgeirsson UP, Cancer Res 1996 56 2013 2016 8616842
39. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Linderholm BK, Hellborg H, Johansson U, Elmberger G, Skoog L, Lehtiö J, Lehtiö J, Lewensohn R, Ann Oncol 2009 20 1639 1646 10.1093/annonc/mdp062 19549711
40. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van Gelder ME, Geurts-Moespot A, van der Kwast TH, Sweep CG, Klijn JG, Cancer Res 2001 61 5407 5414 11454684
41. Sunitinib: from rational design to clinical efficacy. Chow LQM, Eckhardt SG, J Clin Oncol 2007 25 884 896 10.1200/JCO.2006.06.3602 17327610
42. Contrasting hypoxic effects on breast cancer stem cell hierarchy is dependent on ER- status. Harrison H, Rogerson L, Gregson HJ, Brennan KR, Clarke RB, Landberg G, Cancer Res 2013 73 1420 1433 10.1158/0008-5472.CAN-12-2505 23248117
43. Stem cells in human breast cancer. Oliveira LR, Jeffrey SS, Ribeiro-Silva A, Histol Histopathol 2010 25 371 385 20054808
44. Hypoxia-inducible factor 1 promotes primary tumor growth and tumor-initiating cell activity in breast cancer. Schwab LP, Peacock DL, Majumdar D, Ingels JF, Jensen LC, Smith KD, Smith KD, Cushing RC, Seagroves TN, Breast Cancer Res 2012 14 6 10.1186/bcr3087 22225988
45. Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation. Grudzien P, Lo S, Albain KS, Robinson P, Rajan P, Strack PR, Golde TE, Miele L, Foreman KE, Anticancer Res 2010 30 3853 3867 21036696
46. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Singh A, Settleman J, Oncogene 2010 29 4741 4751 10.1038/onc.2010.215 20531305